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1. Introduction
  Ovarian cancer is a malignant cancer which locates 
on ovary, most of ovarian cancers are primary and the 
morbidity is the third among female reproductive system 
malignant cancers which is just next to cervix cancer 
and urine uterine cancer[1,2]. The malignant degree of 
ovarian cancer is high, and affect life quality of patients 
significantly. Morbidity and progress mechanism is the 
key in clinical treatment. High mobility group AT-hook 2 
(HMGA2) is involved in various biological processes such 
as the formation of the embryo and the development of 
malignant cancer[3]. We aimed to analyze its effects on the 
malignant degree, invasion, metastasis, proliferation and 
cellular morphology of ovarian cancer cells. 
2. Materials and methods 
2.1. Materials
2.1.1. Cell lines
  Stable high H-RAS protein expression cell line T29H 
mutated from ovarian cancer epithelial cell lines T29, T80 
and T29 was selected. Ovarian cell lines SKOV3, HEY, 
OVCAR-3, Caov-3 and cells packed by Phonenix virus 
were selected as experimental cell lines in our research[4-6]. 
All above cell lines were purchased from American 
standard center culture collection (American Type Culture 
Collection).
2.1.2. Instruments and equipments
  MTS kits were provided by Promega Corporation for cell 
proliferation and preserved at minus 20℃. 96-well plates 
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were purchased from American Scientific Corporation.
2.1.3. Cell culture media
  The cell culture medias including dulbecco’s modified 
eagle medium, heat inactivated fetal bovine serum, M199 
culture media, epithelial growth factor, complete medium, 
pancreatin-EDTA(0.05% and 0.25%), cell freezing medium, 
and Dulbecco’s phosphate buffered saline were obtained 
from Sigma-Aldrich Corporation, the preparation methods 
were referred to related references[7-11].
2.2. Interference methods
2.2.1. Production of transient transfection reagents
  20 nmol siRNA-HMGA2 (20 毺M) powder was obtained and 
dissolved in 1ml sterilized distilled water to be divided and 
preserved in refrigerator. let-7c and anti-let-7c: 5 nmol
above powder was obtained and dissolved in sterilized 
distilled water without RNA enzyme to be divided and 
preserved in refrigerator. 20 毺M control small RNA was 
obtained and divided to be preserved. Lipofectamine 2000 
was directly preserved in refrigerator at constant 44℃[12,13].
2.2.2. Transfection methods
  The cells were cultured and transfected when the 
confluence was up to 40%-50%[14-19]. to T29A2- and T80A2- 
cells was interfered by HMGA2-siRNA; T29A2+ cells was 
interfered by let-7c. Transfect HMGA2 expressed ovarian 
cancer SKOV3-sh-HMGA2 cell line was established by 
Lentivirus package. SKOV3-pGIPZ was used as control cell 
line. Fluorescent staining was used to verify the interference 
result after 48 h. 
2.3. Observation indicators
  Soft AGAR cloning formation experiment, Matrigel invasion 
assay, growth curve method[20,21]  were applied to observe 
malignant degree of cells, ability of invasion and metastasis, 
and proliferation ability, then the morphological change 
among cells was compared. 
2.4. Statistical analysis
  All date in our study were analyzed by SPSS13.0. 
Enumeration data was analyzed by Chi-square test and 
measurement data was analyzed by t test. The test level was 
set as 毩=0.05. The difference was considered as statistically 
significant when P＜0.05.
3. Results 
3.1. Interference effects
  Florescent staining method showed there was satisfactory 
interference effects in different cells, as shown in Figure 1. 
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Figure 1. Interference effects of siRNA-HMGA2 tested by florescent 
staining.
3.2. Malignant degree
  After the application of siRNA-HMGA2, number of T29A2- 
cell clones was significantly decreased compared with the 
negative control Block-iT (t=13.509, 12.214, respectively, all 
P<0.05). After the application of let-7c, number of T29A2+ 
cell clones was decreased significantly, however, after the 
application of anti-let-7, the number of clones restored, 
and there was no significant difference compared with the 
negative group, as shown in Figure 2. 
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Figure 2. Results of cell line malignant degree by soft AGAR cloning 
formation experiment. 
3.3. Ability of invasion and metastasis
  After interference, the number of T29A2- cells which 
passed through Matrigel polycarbonate membrane was 
significantly lower than the negative control group, as shown 
in Figure 3.   
 
Table 1
Comparison of 96 h cell growth condition(mean依sd).
Type of cell T29A2- T29A2+ SKOV3
HMGA2 interfered 49 885.6依1 827.5 73 855.5依2 629.6   231 829.7依15 338.6
Negative control 69 405.2依4 345.0 99 705.6依3 058.4 402 981.0依6 598.5
t 37.423 22.950 79.365
P ＜0.05 ＜0.05 ＜0.05
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Figure 3. Matrigel invasion assay result of cell line invasion and 
metastasis ability.
3.4. Ability of proliferation
  After the treatment of siRNA-HMGA2, let-7c and sh-
HMGA2 respectively, proliferation of T29A2-, T29A2+ 
and SKOV3 was slower, and the phenomenon was most 
significant in SKOV3, as shown in Table 3 and Fig 4. 
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Figure 4. Growth curve analysis of cell line proliferation ability.
3.5. Cell morphology
  Stable interference of HMGA2 induced mesenchymal-
epithelial changes in morphology of SKOV3-sh-HMGA2 
(Figure 5).
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Figure 5. Cell morphology results.
4. Discussion
  Ovarian cancer is divided in to typeⅠand type Ⅱ, 
malignant degree of type Ⅰincluding mucous carcinoma, 
clear cell carcinoma and endometrioid carcinoma is low, 
however, type Ⅱ has high morbidity and progresses 
rapidly, 5-year survival rate of which is less than 30% 
and there has been no effective therapy[22,23]. Thus, to 
analyze the biological behavior, mechanism of occurrence 
and development has become critical in guiding clinical 
treatment.
  HMGA2 is a gene located at 12q13-15 which can code and 
construct transcriptional factor proteins. Dahiya et al[24-27] 
found that HMGA2 showed significant effects on the nerve 
system development, pituitary adenoma development and 
DNA injury impairment in mouse, and was verified as a 
critical oncoprotein of many malignant cancers. 
  To explore the effects of HMGA2 on malignant degree, 
invasion, metastasis, proliferation and cellular morphology 
of ovarian cancer cells, we applied siRNA, let-7c and anti-
let-7c to interfere the expression of HMGA2. After the 
application of siRNA-HMGA2, number of T29A2- cell clones 
decreased, there was significant difference compared with 
the negative control Block-iT; after the application of Let-
7c, number of T29A2+ cell clones decreased significantly, 
however, after the application of anti-let-7, the number 
of clones restored, indicating that after interference of 
HMGA2 expression, the malignant degree of ovarian cancer 
significantly decreased; Matrigel invasion assay showed the 
ability of ovarian cell invasion and metastasis significantly 
decreased after interference of HMGA2 expression; after 
the treatment of siRNA-HMGA2, let-7c and sh-HMGA2 
respectively, proliferation of T29A2-,T29A2+ and SKOV3 was 
slower, and the phenomenon was most obvious in SKOV3, 
indicating the cell growth and proliferation were affected 
significantly by interference of HMGA2, and the HMGA2 
stably interfered cells were affected most[28]. In observation 
of cellular morphology, we found SKOV3-sh-HMGA2 
cells had mesenchymal-epithelial change after HMGA2 
interference, and epithelial-mesenchymal transition (EMT) 
plays important roles in development of various biological 
processes such as early embryo, invasion and metastasis 
of cancer and fibrosis of chronic inflammation[29,30]. We 
consider that the reason why HMGA2 affects the malignant 
degree, invasion, metastasis, proliferation ability of ovarian 
cancer is that it is involved in the formation of EMT to 
promote the malignant transformation, enhance the ability 
of invasion and metastasis and promote the proliferation of 
cells. Thus ovarian cancer progresses rapidly and affects the 
survival quality.
  In conclusion, we can apply the HMGA2 expression level 
interference as the targeted therapy to inhibit the progress of 
cancer and improve the prognosis. 
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